21 – 30 of 116
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries : A survey
- Contribution to journal › Article
-
Mark
Pneumococcal vaccine in adults with immune-mediated inflammatory diseases
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate : Are They Interchangeable?
- Contribution to journal › Article
-
Mark
High leptin levels in blood are associated with chronic widespread pain in rheumatoid arthritis
- Contribution to journal › Article
-
Mark
Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors
- Contribution to journal › Article
-
Mark
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis : a European routine-care observational study
- Contribution to journal › Article
-
Mark
Second and third TNF inhibitors in European patients with axial spondyloarthritis : effectiveness and impact of the reason for switching
- Contribution to journal › Article
-
Mark
Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy : results from the ICEBIO registry
- Contribution to journal › Article
-
Mark
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis : Results From the European Spondyloarthritis Research Collaboration Network
- Contribution to journal › Article
-
Mark
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs : a Swedish nationwide study (COVID-19-REUMA)
- Contribution to journal › Article
